Custom-Made vaccine takes on melanoma in early trial

NCT ID NCT04930783

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a personalized vaccine called NeoVax, combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab), in 10 people with advanced melanoma. The goal is to see if the combination is safe and helps the immune system recognize and attack cancer cells. Because it's a phase 1 study, the main focus is on side effects and finding the right dose, not yet on curing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized neoantigen vaccine (NeoVax) plus CDX-301 and either nivolumab or pembrolizumab
What this could lead to: If this works, it could point toward a more effective treatment for advanced melanoma by training the immune system to attack cancer cells.
What could go wrong: This is a very early (phase 1) and small (10 people) trial focused on safety, not effectiveness. The personalized vaccine is complex and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA METASTATIC MELANOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.